Sort by
Previous Page Page 1 of 11 Next Page
  1. Research

    Public engagement in setting healthcare priorities: a ranking exercise in Cyprus

    In countries such as Cyprus the financial crisis and the recession have severely affected the funding and priority setting of the health care system. There is evidence highlighting the importance of population...

    Antonis Farmakas, Mamas Theodorou, Petros Galanis, Georgios Karayiannis, Stefanos Ghobrial, Nikos Polyzos, Evridiki Papastavrou, Eirini Agapidaki and Kyriakos Souliotis

    Cost Effectiveness and Resource Allocation 2017 15:16

    Published on: 9 August 2017

  2. Research

    Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus

    As treatments for chronic hepatitis C are moving away from interferon-containing regimens, the most appropriate allocation of resources to higher cost, interferon-free, direct-acting antiviral (DAA) regimens n...

    Phil McEwan, Samantha Webster, Thomas Ward, Michael Brenner, Anupama Kalsekar and Yong Yuan

    Cost Effectiveness and Resource Allocation 2017 15:15

    Published on: 21 July 2017

  3. Research

    Modeling the potential impact of emerging innovations on achievement of Sustainable Development Goals related to maternal, newborn, and child health

    Innovations that improve the affordability, accessibility, or effectiveness of health care played a major role in the Millennium Development Goal achievements and will be critical for reaching the ambitious ne...

    Tara Herrick, Claudia Harner-Jay, Craig Shaffer, Greg Zwisler, Peder Digre and Amie Batson

    Cost Effectiveness and Resource Allocation 2017 15:12

    Published on: 12 July 2017

  4. Research

    Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

    In Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9®) received the European market authorizatio...

    Francesco Saverio Mennini, Paolo Bonanni, Florence Bianic, Chiara de Waure, Gianluca Baio, Giacomo Plazzotta, Mathieu Uhart, Alessandro Rinaldi and Nathalie Largeron

    Cost Effectiveness and Resource Allocation 2017 15:11

    Published on: 11 July 2017

  5. Research

    Cost-effectiveness analysis of the diarrhea alleviation through zinc and oral rehydration therapy (DAZT) program in rural Gujarat India: an application of the net-benefit regression framework

    This study evaluates the cost-effectiveness of the DAZT program for scaling up treatment of acute child diarrhea in Gujarat India using a net-benefit regression framework.

    Samuel D. Shillcutt, Amnesty E. LeFevre, Christa L. Fischer-Walker, Sunita Taneja, Robert E. Black and Sarmila Mazumder

    Cost Effectiveness and Resource Allocation 2017 15:9

    Published on: 8 June 2017

  6. Methodology

    Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

    Ofatumumab (Arzerra®, Novartis) is a treatment for chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab [double refractory (DR-CLL)]. Ofatumumab was licensed on the basis of an uncontrolled Phas...

    Anthony J. Hatswell, Gwilym J. Thompson, Penny A. Maroudas, Oleg Sofrygin and Thomas E. Delea

    Cost Effectiveness and Resource Allocation 2017 15:8

    Published on: 26 May 2017

  7. Review

    Economic evaluations of vaccines in Canada: a scoping review

    This study aims to summarise and describe the evolution of published economic evaluations of vaccines in Canada, thereby outlining the current state of this expanding and meaningful research.

    Ellen R. S. Rafferty, Heather L. Gagnon, Marwa Farag and Cheryl L. Waldner

    Cost Effectiveness and Resource Allocation 2017 15:7

    Published on: 5 May 2017

  8. Research

    Efficiency and productivity assessment of public hospitals in Greece during the crisis period 2009–2012

    This study is an initial effort to examine the dynamics of efficiency and productivity in Greek public hospitals during the first phase of the crisis 2009–2012. Data were collected by the Ministry of Health af...

    P. Xenos, J. Yfantopoulos, M. Nektarios, N. Polyzos, P. Tinios and A. Constantopoulos

    Cost Effectiveness and Resource Allocation 2017 15:6

    Published on: 26 April 2017

  9. Methodology

    Defining a staged-based process for economic and financial evaluations of mHealth programs

    Mobile and wireless technology for health (mHealth) has the potential to improve health outcomes by addressing critical health systems constraints that impede coverage, utilization, and effectiveness of health...

    Amnesty E. LeFevre, Samuel D. Shillcutt, Sean Broomhead, Alain B. Labrique and Tom Jones

    Cost Effectiveness and Resource Allocation 2017 15:5

    Published on: 17 April 2017

  10. Research

    Cost-effectiveness analysis of the national decentralization policy of antiretroviral treatment programme in Zambia

    In resource-limited settings with a high prevalence of human immunodeficiency virus (HIV) infection such as Zambia, decentralization of HIV/acquired immunodeficiency syndrome (HIV/AIDS) treatment and care with...

    Shinsuke Miyano, Gardner Syakantu, Kenichi Komada, Hiroyoshi Endo and Tomohiko Sugishita

    Cost Effectiveness and Resource Allocation 2017 15:4

    Published on: 12 April 2017

  11. Research

    Economic evaluation of participatory learning and action with women’s groups facilitated by Accredited Social Health Activists to improve birth outcomes in rural eastern India

    Neonatal mortality remains unacceptably high in many low and middle-income countries, including India. A community mobilisation intervention using participatory learning and action with women’s groups facilita...

    Rajesh Kumar Sinha, Hassan Haghparast-Bidgoli, Prasanta Kishore Tripathy, Nirmala Nair, Rajkumar Gope, Shibanand Rath and Audrey Prost

    Cost Effectiveness and Resource Allocation 2017 15:2

    Published on: 21 March 2017

  12. Review

    International lessons in new methods for grading and integrating cost effectiveness evidence into clinical practice guidelines

    Economic evidence is influential in health technology assessment world-wide. Clinical Practice Guidelines (CPG) can enable economists to include economic information on health care provision. Application of ec...

    Kathryn M. Antioch, Michael F. Drummond, Louis W. Niessen and Hindrik Vondeling

    Cost Effectiveness and Resource Allocation 2017 15:1

    Published on: 10 February 2017

  13. Research

    Optimizing treatment for the prevention of pre-eclampsia/eclampsia in Nepal: is calcium supplementation during pregnancy cost-effective?

    In Nepal, pre-eclampsia/eclampsia (PE/E) causes an estimated 21% of maternal deaths annually and contributes to adverse neonatal birth outcomes. Calcium supplementation has been shown to reduce the risk of PE/...

    Isabelle Feldhaus, Amnesty E. LeFevre, Chandra Rai, Jona Bhattarai, Deirdre Russo, Barbara Rawlins, Pushpa Chaudhary and Kusum Thapa

    Cost Effectiveness and Resource Allocation 2016 14:13

    Published on: 28 December 2016

  14. Review

    Advancing aged care: a systematic review of economic evaluations of workforce structures and care processes in a residential care setting

    Long-term care for older people is provided in both residential and non-residential settings, with residential settings tending to cater for individuals with higher care needs. Evidence relating to the costs a...

    Tiffany Easton, Rachel Milte, Maria Crotty and Julie Ratcliffe

    Cost Effectiveness and Resource Allocation 2016 14:12

    Published on: 12 December 2016

  15. Research

    What are we paying for? A cost-effectiveness analysis of patented denosumab and generic alendronate for postmenopausal osteoporotic women in Australia

    Zoledronic acid and denosumab were funded by the Australian government for the management of osteoporosis at an equivalent price to alendronate. The price of alendronate has declined by around 65 %, but the pr...

    Jonathan Karnon, Ainul Shakirah Shafie, Nneka Orji and Sofoora Kawsar Usman

    Cost Effectiveness and Resource Allocation 2016 14:11

    Published on: 13 October 2016

  16. Research

    Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis

    The coverage of prevention and treatment strategies for ischemic heart disease and stroke is very low in Ethiopia. In view of Ethiopia’s meager healthcare budget, it is important to identify the most cost-effe...

    Mieraf Taddesse Tolla, Ole Frithjof Norheim, Solomon Tessema Memirie, Senbeta Guteta Abdisa, Awel Ababulgu, Degu Jerene, Melanie Bertram, Kirsten Strand, Stéphane Verguet and Kjell Arne Johansson

    Cost Effectiveness and Resource Allocation 2016 14:10

    Published on: 12 August 2016

  17. Research

    Mothers’ willingness to pay for HPV vaccines in Anambra state, Nigeria: a cross sectional contingent valuation study

    Human papilloma virus (HPV) vaccination in Nigeria will require substantial financing due to high cost of HPV vaccine and inexistence of structures to support adolescent vaccination. Alternative sources are ne...

    Ifeoma Blessing Umeh, Sunday Odunke Nduka and Obinna Ikechukwu Ekwunife

    Cost Effectiveness and Resource Allocation 2016 14:8

    Published on: 6 June 2016

  18. Research

    Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema

    To conduct a cost-utility analysis of ranibizumab versus aflibercept for the treatment of patients with visual impairment due to diabetic macular edema (DME) in the Greek setting.

    Georgia Kourlaba, John Relakis, Ronan Mahon, Maria Kalogeropoulou, Georgia Pantelopoulou, Olga Kousidou and Nikos Maniadakis

    Cost Effectiveness and Resource Allocation 2016 14:7

    Published on: 14 April 2016

  19. Research

    The value of using a brain laser interstitial thermal therapy (LITT) system in patients presenting with high grade gliomas where maximal safe resection may not be feasible

    The objective of this analysis was to determine the value (incremental cost/increment benefit) of a brain LITT system versus employing current surgical options recommended by NCCN guidelines, specifically open...

    Jeffrey D. Voigt and Gene Barnett

    Cost Effectiveness and Resource Allocation 2016 14:6

    Published on: 21 March 2016

  20. Reviewer acknowledgement

    Annual acknowledgement of manuscript reviewers

    The editors of Cost Effectiveness and Resource Allocation would like to thank all our reviewers who have contributed to the journal in volume 13 (2015).

    Joan Rovira

    Cost Effectiveness and Resource Allocation 2016 14:5

    Published on: 11 March 2016

Previous Page Page 1 of 11 Next Page